DUBLIN, May 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will present at the Deutsche Bank 43^rd Annual Health Care Conference in Boston, Massachusetts. The presentation will begin at 10:40 a.m. Eastern Time on Tuesday, May 8, 2018.

DUBLIN and CAMBRIDGE, Mass., May 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, announced today the launch of the AboutYourGut.com website. On the heels of IBS Awareness Month, the hub's mission is to help educate sufferers impacted by irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) on these conditions, including providing information on condition management. The website is designed to resonate with people who are seeking an empathetic, optimistic and balanced point of view, offering expertly curated content as well as streamlined condition information, all within a clean, easy-to-navigate interface.

DUBLIN, April 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its first quarter 2018 continuing operations performance. Total first quarter 2018 net revenues were $3.67 billion, a 2.8 percent increase from the prior year quarter. Executive Commentary
"2018 is off to a strong start for Allergan with our first quarter results demonstrating solid execution on all fronts, including the R&D pipeline. Allergan is clearly focused on strong operational performance and disciplined capital allocation," said Brent Saunders, Chairman and CEO of Allergan. "Allergan revenues grew 3 percent driven by a 13 percent increase in our core business amid exclusivity challenges for older products, and our tight expense management enabled maintenance of strong margins. We drove strong cash flow, continued to pay down debt to further de-lever our balance sheet while accelerating and completing our $2 billion share repurchase program."

DUBLIN, April 27, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE II (UBR-MD-02), the second of two pivotal Phase 3 clinical trials evaluating the efficacy, safety and tolerability of orally administered ubrogepant 25 mg and ubrogepant 50 mg compared to placebo in a single migraine attack in adults. Allergan anticipates filing of a New Drug Application (NDA) to the FDA in 2019.

DUBLIN, April 26, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, will present new data at the annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Austin, Texas from April 27-30, 2018. Included is a post-hoc, exploratory, integrated analysis regarding impact on fibroid volume from the pivotal VENUS I and II trials for ulipristal acetate, a drug under investigation in the U.S. for the treatment of abnormal uterine bleeding in women with uterine fibroids. The data have been accepted for ePoster presentation at the meeting.

DUBLIN, April 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that 19 Allergan-supported abstracts were selected for poster presentations at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii from April 29, 2018 through May 3, 2018.

DUBLIN, April 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company announced today that the company will share 25 presentations at the 70^th Annual American Academy of Neurology (AAN) Meeting, including five oral podium presentations. Five presentations will focus on migraine and one will spotlight the clinical trial results evaluating the safety and efficacy of onabotulinumtoxinA in treating lower limb spasticity in children ages 2-16. Results of the Phase 3 ACHIEVE I study of ubrogepant, an investigational oral calcitonin gene-related peptide (CGRP) for acute treatment of migraine, were selected as an emerging science "data blitz" presentation and poster to be presented on April 24^th at 5:45 pm PT.

DUBLIN, April 19, 2018 /PRNewswire/ -- In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire. Allergan continues its ongoing process of evaluating a full range of potential strategic actions that will create value for shareholders, such as divestitures, combinations and acquisitions.

DUBLIN, April 19, 2018 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "TAKEOVER CODE") AND THERE CAN BE NO CERTAINTY THAT ANY SUCH OFFER WILL BE MADE NOR AS TO THE TERMS ON WHICH ANY SUCH OFFER WOULD BE MADE.

DUBLIN, April 13, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the official launch of TrueTear^®, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. TrueTear^®, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to induce the production of natural tears, is a novel and innovative approach for those patients with inadequate tear production. In two clinical trials, TrueTear^® was shown to be safe and effective for temporarily increasing tear production in adult patients.